Rigel Pharmaceuticals announced that a paper presenting a post-hoc data analysis of Tavalisse (fostamatinib disodium hexahydrate) tablets, as well as accompanying commentary have been published in the British Journal of Haematology. Tavalisse, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, is indicated for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Rigel conducted the post-hoc data analysis, which has previously been presented, from a Phase III clinical program of Tavalisse in adult patients with ITP. The published data analysis and accompanying commentary highlight the higher response rate and decrease in bleeding incidents in ITP patients receiving Tavalisse as a second-line therapy.
In this analysis, 32 patients received fostamatinib as a second-line therapy, of which, 78% (25/32) achieved at least 1 platelet count of at least 50,000/µL while on treatment (without rescue therapy). Adverse events were manageable and consistent with those previously reported with fostamatinib.
See: “Fostamatinib is an effective second?line therapy in patients with immune thrombocytopenia” Ralph Boccia et al. British Journal of Haematology 23 July 2020 online only doi/10.1111/bjh.16959